ALIAS 2: Albumin in Acute Stroke
This study will ascertain whether high-dose human albumin (ALB) therapy confers neuroprotection in acute ischemic stroke over and above best standard of care as determined by proportion of patients with favorable outcome in treatment versus placebo groups at 90 days from randomization.
PAO: Feasibility and Safety of NeuroFlo in Patients with Persistent Arterial Occlusion After Attempted Thrombectomy with the Merci Retriever System
This study will assess the safety and feasibility of the NeuroFlo? catheter in treating ischemic stroke patients with persistent arterial occlusion following attempted thrombectomy. A maximum of 20 evaluable patients will be enrolled at the University of California, Los Angeles.
Clinical Study MP-124-A01
This Phase I, first-in-human study will assess the safety, tolerability, and pharmacokinetics of ascending 24- and 72- hour, continuous infusions of various doses of the neuroprotectant MP-124 in acute, ischemic stroke patients. 72 patients will be enrolled across twenty-three centers.
IMS III: Interventional Management of Stroke
This study will investigate whether ischemic stroke patients with a baseline NIHSS of 10 or greater treated with recombinant tissue plasminogen activator utilizing a combined intravenous plus intra-arterial (IV/IA) approach to recanalization started within 3 hours of onset, are more likely to have a favorable outcome at 3 months as compared to subjects treated with standard IV rt-PA alone.
MR RESCUE: Magnetic Resonance and Recanalization of Stroke Clots Using Embolectomy
This trial will evaluate whether use of MRI is a rational and appropriate selection criterion for mechanical recanalization therapy for acute ischemic stroke. A positive trial will suggest substantial clinical benefit from embolectomy therapy in the group of patients with a penumbral MRI pattern, and permit informed design of definitive phase 3 trials of endovascular embolectomy.
Patients between the ages of 18 and 85 who present within 8 hours with acute ischemic stroke occurring in the MCA territory are eligible for enrollment. They are randomized to either treatment with the Merci Retriever® or best medical management. They must be eligible for MRI in order to be enrolled. 120 patients will be enrolled nationwide at 30 centers.
FAST-MAG: Field Administration of Stroke Therapy-Magnesium
The Field Administration of Stroke Therapy-Magnesium (FAST-MAG) trial will examine if magnesium sulfate can protect the threatened brain when administered to stroke victims by paramedics within the first two hours of stroke onset. Magnesium sulfate works by dilating brain blood vessels and by preventing buildup of damaging calcium in injured nerve cells.
The National Institutes of Health-funded FAST-MAG trial is the first large-scale trial of neuroprotective therapy delivery to stroke patients in ambulances.
The FAST-MAG trial will be performed in conjunction with paramedics from the Los Angeles Fire Department, as well as emergency physicians, neurologists and nurses throughout Los Angeles County.
SENTIS: Safety and Efficacy of Neuro-Flow Technology in Ischemic Stroke
This study will investigate the safety and efficacy of the NeuroFlo? treatment plus medical treatment relative to medical treatment alone in improving neurological outcome in the ischemic stroke patients
The NeuroFlo device is a dual balloon aortic catheter. The device is inserted through the femoral artery into the abdominal aorta and positioned so that the proximal and distal balloons are above and below the renal artery. The balloons are then inflated to reduce luminar area by 70% for 45 minutes. This reduces, but doesn't occlude blood flow to the lower part of the body. Dual balloons and pressure measurements create a stable, controlled 70% occlusion. Cerebral perfusion increases average 30%+ and persist beyond balloon deflation.
Acute Biomarkers and Clinical Study (ABCs) of Stroke
This study will involve the collection of blood samples and clinical information that can be stored and later analyzed for information that may lead to new discoveries about stroke. 8 centers across the United States will be participating as part of the SPOTRIAS Network.
SIRRACT: Stroke Inpatient Rehabilitation Reinforcement of ACTivity
The Stroke Inpatient Rehabilitation Reinforcement of ACTivity (SIRRACT) trial will utilize triaxial accelerometers worn on the ankles and algorithms developed by UCLA engineers that reveal the type, quantity, and aspects of quality of exercises and training to walk during their initial rehabilitation. This randomized, international, multi-center clinical trial will bring these measures into daily care to monitor activity on the inpatient rehabilitation unit, assess compliance with exercise and skills practice, and test the utility of providing feedback to patients about the type and quantity of their daily skills practice and exercise.
